ZVSA heads into its May 19 Q1 earnings release with its ORTEX short score climbing steadily all week — even as short interest itself quietly trims back from a month ago.
The short score is the most interesting signal here. It has risen every single session this week, reaching 69.6 on May 12 from 65.9 a week earlier — a four-point gain across five days. That climb reflects not just the level of short interest but the broader setup: borrow tightness, share availability, and positioning all feeding into a score that now ranks in roughly the 70th percentile of the universe. At the same time, actual short interest — about 2.1% of the free float — is modest in absolute terms and has drifted roughly 7% lower over the past month. The score is rising not because shorts are piling in, but because the lending dynamics have tightened around a relatively small borrowed position.
The borrow market tells a nuanced story. Availability runs at about 89% of short interest — meaning there are roughly nine shares available to borrow for every ten already lent out. That is on the tighter side of the range, though not extreme. The cost to borrow has been running near 18–19% annualised through late April and early May, a level that has been broadly stable for months aside from a brief spike to over 160% on April 17 that appears to be a data anomaly rather than a genuine market event. At 18.8%, borrow is expensive relative to most listed equities but consistent with what a micro-cap OTC biotech commands. Lending availability has held in the 67%–82% utilisation range over the past six weeks, suggesting the pool is meaningfully committed without being fully exhausted. The 52-week peak in utilisation was 100% — so today's ~75% reading is elevated but not at the historic extreme.
The earnings backdrop adds context. ZyVersa reported full-year 2025 results in late March, posting a net loss of $24.95 million — wider than the $9.41 million loss a year earlier, though loss per share improved sharply on a larger share count. Then, the day after the official report date, Q1 figures were also published: EPS came in at -$0.22, a meaningful improvement from -$0.73 in the same quarter a year ago. The previous two earnings events produced a 1-day decline of 8.5% and a flat open respectively, before both eventually drifted lower over five days. There is no established pattern of a sharp positive reaction. The next scheduled event — likely Q1 2026 results — is pencilled in for May 19.
What to watch is whether the short score continues its upward drift through the earnings date, and whether the borrow market tightens further as the report approaches.
See the live data behind this article on ORTEX.
Open ZVSA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
